Compare Repligen Corporation Common Stock (RGEN) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs State Street Real Estate Select Sector SPDR ETF — how do they compare? Repligen Corporation Common Stock trades at $178.86 (market cap $11.14B), while State Street Real Estate Select Sector SPDR ETF trades at $41.83 (market cap $7.83B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, State Street Real Estate Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and State Street Real Estate Select Sector SPDR ETF for 77 Days on average.
| RGEN | XLRE | |
|---|---|---|
Market Cap | $11.14B | $7.83B |
Volume | 1,259,263 | 5,853,296 |
Sector | Health | Sector/Thematic |
52-Week High | $194.57 | $46.01 |
52-Week Low | $102.87 | $40.01 |
Typical Hold Time | 0 Days | 77 Days |
Enterprise Value | $11.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
XLRE, the State Street Real Estate Select Sector SPDR ETF, trades at $41.83, down 0.21% on the day. The technical outlook is mixed, with a bullish overall signal but bearish moving averages. Key financial ratios are not available in the provided data. Recent news highlights the fund's low expense ratio of 0.08% and its focus on 30 U.S. large-cap real estate holdings, positioning it as a cost-effective domestic real estate exposure tool.
The outlook for XLRE is influenced by competing factors: its low-cost structure is a strength, but the sector faces headwinds from rising bond yields and potential interest rate volatility. Investment opportunity lies in its role as a pure-play U.S. real estate ETF, while risks include macroeconomic sensitivity and competition from more diversified or thematic real estate funds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
